A5056123638- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- vaccines and immunoinformatics approaches
- CAR-T cell therapy research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Liver Disease Diagnosis and Treatment
- Petri Nets in System Modeling
- Immune Cell Function and Interaction
- Hepatocellular Carcinoma Treatment and Prognosis
- Distributed and Parallel Computing Systems
- Ferroptosis and cancer prognosis
- Viral-associated cancers and disorders
- Gallbladder and Bile Duct Disorders
- Distributed systems and fault tolerance
The First Affiliated Hospital, Sun Yat-sen University
2022-2024
Sun Yat-sen University
2022-2024
Abstract A high rate of recurrence after curative therapy is a major challenge for the management hepatocellular carcinoma (HCC). Currently, no effective adjuvant available to prevent HCC recurrence. We designed personalized neoantigen-loaded dendritic cell vaccine and neoantigen-activated T-cell therapy, used it as treat 10 patients with who had undergone resection or radiofrequency ablation in first stage phase II trial (NCT03067493). The primary outcomes were safety neoantigen-specific...
Reports showed that some of intrahepatic cholangiocarcinoma (ICC) patients with lymph node metastasis (LNM) may also gain survival benefit undergone resection. However, the effect extent LNM on prognosis and surgical indication is barely discussed.From September 1994 to November 2018, primary ICC initial curable surgery were enrolled. Based LNM, we divided these into 4 groups, including no (group N0), hepatoduodenal ligament or common hepatic artery (region A, group A), gastrohepatic nodes...
Prompts to large language models (LLMs) have evolved beyond simple user questions. For LLMs solve complex problems, today's practices include domain-specific instructions, illustration of tool usages, and long context, such as textbook chapters in prompts. As such, many parts prompts are repetitive across requests, their attention computation results can be reused. However, LLM serving systems treat every request isolation, missing the opportunity reuse. This paper proposes Preble, first...
e16267 Background: Prognoses of patients with hepatocellular carcinoma (HCC) remain unsatisfactory due to the high recurrence rate after curative hepatectomy. In this study, we investigated safety and efficacy neoadjuvant Cadonilimab (PD-1/CTLA-4, a bi-specific antibody) in combination transarterial chemoembolization(TACE) for risk. Methods: For phase II, single-centre, single-arm trial, resectable HCC (BCLC stage A/B) participants were enrolled, who should meet at least one following...
<div>Abstract<p>A high rate of recurrence after curative therapy is a major challenge for the management hepatocellular carcinoma (HCC). Currently, no effective adjuvant available to prevent HCC recurrence. We designed personalized neoantigen-loaded dendritic cell vaccine and neoantigen-activated T-cell therapy, used it as treat 10 patients with who had undergone resection or radiofrequency ablation in first stage phase II trial (NCT03067493). The primary outcomes were safety...
<div>Abstract<p>A high rate of recurrence after curative therapy is a major challenge for the management hepatocellular carcinoma (HCC). Currently, no effective adjuvant available to prevent HCC recurrence. We designed personalized neoantigen-loaded dendritic cell vaccine and neoantigen-activated T-cell therapy, used it as treat 10 patients with who had undergone resection or radiofrequency ablation in first stage phase II trial (NCT03067493). The primary outcomes were safety...
Supplementary Figure from Combination Neoantigen-Based Dendritic Cell Vaccination and Adoptive T-Cell Transfer Induces Antitumor Responses Against Recurrence of Hepatocellular Carcinoma
Supplementary Figure from Combination Neoantigen-Based Dendritic Cell Vaccination and Adoptive T-Cell Transfer Induces Antitumor Responses Against Recurrence of Hepatocellular Carcinoma